Traws Pharma, Inc. Q2 FY2025 earnings call

• Traws reprioritized clinical trial plans. In the COVID program, a Phase II study of ratutrelvir in newly diagnosed COVID patients vs PAXLOVID was submitted to HREC, and a single-arm study for PAXLOVID-ineligible patients was proposed, with results expected by year-end 2025.
• For the influenza program, constructive discussions with BARDA regarding tivoxavir marboxil in stockpiling for influenza, including bird flu, were ongoing. Bird flu in the US wasn't at pandemic levels yet, but Tivoxavir marboxil was developed for bird flu.
• Legacy oncology assets: Rigosertib showed compelling efficacy in RDEB, with efforts to find partnerships to advance it.

In the second quarter of 2025, Traws Pharma had revenue of $2.7 million, compared to $57,000 in the same period of 2024. Research and development expense was $2.3 million in Q2 2025 versus $4 million in Q2 2024. General and administrative expense was $1.7 million in Q2 2025 compared to $2 million in Q2 2024. The net loss for Q2 2025 was $0.9 million, with the net loss per basic and diluted common share at $0.11, contrasting with a much larger net loss in Q2 2024.

• Reprioritized clinical trials to reflect short- and medium-term shareholder value. Expect Phase II results of ratutrelvir by year-end 2025.
• Continue constructive discussions with BARDA for tivoxavir marboxil in the drug stockpiling initiative for influenza.

• Forward-looking statements involve risks and uncertainties where actual results may differ materially from those projected. Risks include clinical trial outcomes not meeting expectations, regulatory hurdles in getting approvals, and market acceptance of products being uncertain.

Q: A: Q: A: